Background {#Sec1}
==========

Hereditary breast cancers account for approximately 10% of all breast cancers, and approximately 23% of all ovarian cancers are considered hereditary \[[@CR1], [@CR2]\]. According to *Plakhins* et al., *BRCA1* pathogenic founder mutations (c.4035delA, c.5266dupC) contribute to 3.77% of all consecutive primary breast cancers and 9.9% of all consecutive primary ovarian cancers \[[@CR3]\]. *BRCA1* and *BRCA2* pathogenic founder mutation analysis is a relatively straightforward and cost-effective screening strategy to identify mutation carriers \[[@CR4]\]. In Latvia, all consecutive breast and ovarian cancer cases are eligible for *BRCA1* pathogenic founder mutations (c.181 T \> G, c.4035delA, c.5266dupC) screening \[[@CR5]\], and the costs of the test are covered by the public health care system. However, according to recent studies, non-founder *BRCA1* and *BRCA2* pathogenic mutations account for up to 21.6% of all *BRCA1* and *BRCA2* pathogenic mutations in the Aschkenazi Jewish population \[[@CR6], [@CR7]\]. There is little information about pathogenic *BRCA1/2* non-founder mutations in Latvia. In a study published by *Berzina* et al., pathogenic non-founder mutations in *BRCA1* and *BRCA2* were identified in 4 out of 30 high-risk breast/ovarian cancer families from the Latvian population \[[@CR8]\]. In another study published by *Tihomirova* et al., non-founder pathogenic mutations in *BRCA1* and *BRCA2* were detected in 9 out of 160 patients with breast and ovarian cancer \[[@CR5]\]. These findings suggest that the proportion of pathogenic *BRCA1/2* non-founder mutations is small and that family cancer history alone is of limited value to find subgroups of individuals, where expensive complete *BRCA1/2* testing is indicated.

The remaining hereditary breast and ovarian cancer cases are associated with mutations in other breast and ovarian cancer susceptibility genes, such as *BRCA1/2*, *TP53*, *PTEN*, *CDH1*, *STK11*, *MLH1*, *MSH2*, *MSH6*, *PMS2*, *PALB2*, *CHEK2*, *ATM*, *RAD51C*, *RAD51D*, *BRIP1* and other \[[@CR9]\]. Patients and their relatives harbouring mutations in hereditary cancer predisposing genes could benefit prevention and screening strategies or novel therapeutic approaches \[[@CR10], [@CR11]\]. Advances in next-generation sequencing allowed the implementation of low-cost multi-gene panel testing in clinical practice to detect pathogenic mutations in hereditary cancer predisposing genes \[[@CR12]\].

Therefore, knowledge of the frequency and phenotypical features of pathogenic mutations beyond *BRCA1* pathogenic founder mutations in *breast* and *ovarian cancer* susceptibility genes is essential for determining the role of second-line testing with multi-gene panels in counselling unsolved *high-risk breast and ovarian cancer patients.*

The aim of the study was to evaluate the rate of pathogenic mutations in the 26 breast and ovarian cancer susceptibility genes in patients who meet the criteria for *BRCA1/2* testing and to compare the accuracy of different selection criteria for second-line testing in a founder population.

Methods {#Sec2}
=======

Patient group {#Sec3}
-------------

Sixteen sequential patients with primary breast and/or ovarian cancer who met all inclusion criteria were included in the study between October 2016 and August 2017. The inclusion criteria were as follows: 1) fulfil at least one of the National Comprehensive Cancer network (NCCN) *BRCA1/2* testing criteria (Table [1](#Tab1){ref-type="table"}) ([www.nccn.org](http://www.nccn.org)); 2) previously *tested negative* for *BRCA1* pathogenic founder mutations (c.181 T \> G, c.4035delA, c.5266dupC); 3) *able to cover* the *cost* of the 26 multi-gene *tests.*Table 1NCCN selection criteria for screening of mutations in *BRCA1*and *BRCA*2At least one of the following criteria has to be met:1. Personal history of breast cancer diagnosed \< age 45 years2. Personal history of breast cancer diagnosed \< age 50 years and at least one case of breast cancer at any age in close blood relative3. Personal history of triple negative breast cancer diagnosed \< age 60 years4. Personal history of breast cancer diagnosed at any age and at least two cases of breast cancer diagnosed at any age or at least one close blood relative with breast cancer diagnosed ≤50 years or at least one blood relative with ovarian carcinoma or a close male blood relative with breast cancer5. Personal history of ovarian cancer6. Personal history of male breast cancer

The following clinical information was obtained: age at testing, personal cancer history, age at cancer diagnosis, breast and/or ovarian cancer pathology, *BRCA1/2* testing history, a family cancer history that covers a 3-generation pedigree according to probands information. The median patient age was 45.6 years (33--63 years). Fifteen out of 16 (93.75%) patients were females, and 1 out of 16 (6.25%) patients was male. Thirteen patients had unilateral breast cancer, 1 patient had bilateral breast cancer, 1 patient had ovarian cancer, and in 1 patient had both breast and ovarian cancer. Four out of 16 (25%) breast cancers were luminal-like HER2 negative, 2 out of 16 (12.5%) breast cancers were luminal B HER2 positive, 8 out of 16 (50%) breast cancers were triple-negative, and 1 out of 16 (6.25%) breast cancers was HER2 positive. The patient characteristics are summarized in Table [2](#Tab2){ref-type="table"}.Table 2The baseline characteristics of patient groupNr.Probands age at diagnosis (years)Primary cancer siteMorphological subtypeBreast cancersubtypeTumor gradeFamily history154BreastDuctalLuminalmissingMother and maternal aunt -- breast cancer age 60; daughter - polycytemia vera age15, brother -- melanoma age 60240BreastDuctalTriple-negative\*G3Mother - Breast and ovarian cancer age 40333 and 38Left Breast/ Right BreastDuctal/ DuctalTriple-negative/ LuminalG3/G3Paternal grandmother - unknown primary gynecological cancer age 50463Breast and OvariesDuctalTriple-negativeG2Mother with breast cancer age 55; sister - ovarian cancer age 59537OvariesNANANAMother - breast cancer age 64658BreastLobularLuminalG2Mother and maternal aunt -- breast cancer age \> 60743BreastDuctalTriple-negativeG3No842BreastDuctal/MedullaryTriple-negativeG2Mother - breast cancer age 60950BreastDuctalTriple-negativeG3Mother - breast cancer age 521035BreastDuctalTriple-negativeG3Mother - breast cancer age 461152BreastDuctalLuminal B HER2 positiveG2Mother and maternal aunt -- breast cancer age \> 501241BreastDuctalHER2 positiveG3No1353BreastDuctalTriple-negativemissingNo1436BreastDuctalLuminalmissingNo1553BreastDuctalLuminalmissingMother and maternal grandmother -- breast cancer age \> 60 years1640BreastDuctalLuminal B HER2 positivemissingNo

### DNA testing {#Sec4}

Informed consent for genetic testing was obtained for all patients. All patients underwent DNA testing with a 26-gene panel (myBRCA HiRisk Hereditary Breast and Ovarian Cancer screening Test, VeritasGenetics, USA) that is a targeted next-generation sequencing assay for the detection of mutations in 26 breast and ovarian cancer susceptibility genes. The genes included high-penetrance breast-ovarian genes (*BRCA1, BRCA2, PTEN, TP53, CDH1, STK11, PALB2*), moderate-penetrance breast and/or ovarian genes (*CHEK2, BRIP1, ATM*), and additional genes (*BARD1, BLM, EPCAM, RAD50, RAD51C, RAD51D, MEN1, MRE11A, MUTYH MSH2, MLH1, NBN, MSH6, PMS2, FAM175A, XRCC2)*. In all patients, the test was performed using saliva. The specificity and sensitivity of the assay are 99.9% for point mutations and small insertions/deletions in the 24 sequenced genes and 99.9% for structural variations in *BRCA1* and *BRCA2*.

### Statistical analysis {#Sec5}

The specificity, sensitivity and accuracy of the NCCN criteria, Manchester scoring system and Swedish Breast cancer group criteria for the prediction of pathogenic non-founder mutations were evaluated. The Manchester score of 15 points threshold was used to assess the likelihood of *BRCA1/2* pathogenic mutation \[[@CR13]\]*.* The specificity, sensitivity and accuracy of different selection criteria for *BRCA1/2* testing in our cohort were calculated using *MedCalc* Statistical Software version 17.9.

Results {#Sec6}
=======

In seven out of sixteen (44%) patients included, pathogenic non-founder *BRCA1/2* mutations were identified. Six patients carried pathogenic variants of *BRCA1* and one of *BRCA2*. In four patients, variants of uncertain significance of *BRCA2*, *RAD50, MRE11A* and *CDH1* were found. Detailed results are shown in Table [3](#Tab3){ref-type="table"}. The NCCN criteria showed a high sensitivity (100%) with low specificity (50%) for the prediction of non-founder pathogenic *BRCA1/2* mutations. The Swedish Breast cancer group criteria showed a low sensitivity (57.1%) with three false negative results. The Manchester scoring system showed a high accuracy (87.5%) for the prediction of pathogenic non-founder *BRCA1/2* mutations with high sensitivity (85.7%) and specificity (88.9%). The sensitivity, specificity and accuracy of different criteria/scoring systems for the detection of probability of *BRCA1/2* pathogenic mutations in our cohort are compared in Table [4](#Tab4){ref-type="table"}.Table 3ResultsNr.MutationClinical significance of mutationNCCN inclusion criteriaManchester score \[[@CR13]\]Swedish Breast cancer group criteria for screening of mutation in *BRCA1* and *BRCA2*1RAD50c.980G \> AVUSNCCN417One case of male breast cancer2BRCA1c.5075-?\_5152 +?delPATNCCN229One case of triple-negative breast cancer ≤age 403BRCA1c.1-?\_c.134 +?delPATNCCN320One case of breast cancer ≤age 354BRCA2c.6998dupTPATNCCN419Breast cancer and ovarian cancer in one individual.5BRCA1c.5117G \> APATNCCN515Do not match6RAD50c.251 T \> AVUSNCCN4MRE11Ac.1715G \> AVUS6NA7BRCA1c.1961delAPATNCCN314Do not match8BRCA2c.280C \> TVUSNCCN414Do not match9BRCA1c.5117G \> APATNCCN416Do not match10BRCA1c.4996_4997dupTAPATNCCN420One case of triple-negative breast cancer ≤age 4011NegativeNegativeNCCN42Do not match12NegativeNegativeNCCN12Do not match13NegativeNegativeNCCN38Do not match14NegativeNegativeNCCN18Do not match15CDH1 c.808 T \> GVUSNCCN48Do not match16NegativeNegativeNCCN10Do not match*PAT*, pathological; *VUS*, variant of uncertain significance; \*Triple-negative breast cancer was defined as ER-0%; PR-0%; HER2- negative;Table 4Comparison of different selection criteria for *BRCA1/2* testing in our cohortCriteriaSensitivitySpecificityAccuracyNCCN100%50%64%Manchester scoring system85.7%88.9%87.5%Swedish Breast cancer group57.1%88.9%75%

Discussion {#Sec7}
==========

Our study is the first report on the use of a 26 *gene panel* in to examine breast and ovarian cancer susceptibility genes in patients in Latvia. We demonstrated a high frequency of pathogenic non-founder germline mutations in *BRCA1* and *BRCA2* genes. In seven out of sixteen (44%) primary breast and ovarian cancer patients matching the criteria for *BRCA1/2* testing pathogenic non-founder *BRCA1/2* mutations were identified. All 7 pathogenic mutations, including 2 large deletions, are novel in populations of Latvia \[[@CR5], [@CR8]\]. These results may suggest that the present practice of testing only the 3 most frequent *BRCA1* pathogenic founder mutations is insufficient and fails to detect a considerable number of pathogenic mutations in *BRCA1/2*. However, our study comprises a relatively small cohort of selected patients. In a study published by *Frank* et al.*,* 21.6% of patients with Ashkenazi ancestry pathogenic non-founder *BRCA1* and *BRCA2* mutations were identified \[[@CR6]\]. In contrast, in the Finnish population of high-risk individuals tested negative for 28 *BRCA1/2* pathogenic founder mutations, additional pathogenic mutations in *BRCA1* and *BRCA2* accounted for just 1.2% \[[@CR12]\]. Much larger numbers are necessary to assess the real proportion of pathogenic non-founder mutations in the population of Latvia.

Despite the drawbacks of such a small study group, the initial results raised some observations.

Interestingly, probands that carried a pathogenic non-founder mutation had some common features. All six breast cancer patients in our study with proven pathogenic non-founder *BRCA1/*2 mutations had a triple-negative phenotype. It is well established that approximately 80% of all *BRCA1/2*-- related tumours have a triple-negative phenotype \[[@CR14]--[@CR18]\]. The prevalence of pathogenic germline *BRCA1/2* mutations in the selected triple-negative breast cancer patients ranged from 9.2 to 34.4% \[[@CR19]--[@CR22]\]. Additional analyses of cDNA microarray data from van't Veer showed that *BRCA1-*related tumours have a sporadic basal-like breast cancer gene expression profile \[[@CR23]\]. Additionally, according to *Richardson* et al., loss of BRCA1 function could play a role in the development of basal-like breast cancers \[[@CR24]\]. *Couch* et al. identified *BRCA1/2* pathogenic mutations in 11.2% of triple-negative breast cancer patients and other breast-ovarian cancer predisposing gene mutations in 3.7% of triple-negative breast cancer patients \[[@CR25]\].

In our study we used the NCCN criteria for screening pathogenic mutations in *BRCA1* and *BRCA*2, where triple-negative breast cancer is used as a criterion together with an age limit \< 60. Only one out of six breast cancer patients in our study who carried a pathogenic *BRCA1/2* non-founder mutation was older than 60 years of age, but in this case, family cancer history was positive in the study published by *Couch* et al.*,* 3.1% of triple-negative breast cancer patients older than 60 years and only 1.4% with no family history of breast or ovarian cancer were diagnosed with *BRCA1/2* pathogenic mutation \[[@CR25]\]. Therefore, our study results support the current NCCN guidelines for screening all triple-negative breast cancer patients younger than 60 years of age.

In contrast, the application of the upper age limit for triple-negative breast cancer patients of 40 years (Swedish Breast cancer group criteria for screening for mutations in *BRCA1* and *BRCA2*) would miss several *BRCA*-positive cases in our cohort \[[@CR26]\].

Our small study showed the high accuracy of the Manchester scoring system for the prediction of pathogenic non-founder *BRCA1/2* mutations in founder mutation-negative patients. Our finding is supported by several other studies performed on the validation of the Manchester scoring system in populations of UK, Germany and South East Asia \[[@CR13], [@CR27], [@CR28]\]. However, larger numbers of cases are needed for comprehensive *validation* of these criteria in the population of Latvia.

Additionally, three out of eight patients tested negative for 26 breast and ovarian cancer susceptibility genes were HER2 positive. According to a recently published study*,* only 9% of *BRCA1*-related breast tumours and 13% of *BRCA2*-related breast tumours were HER2 positive \[[@CR29]\]. HER2 positivity is also included in the Manchester scoring system as a *BRCA1/2* probability decreasing factor \[[@CR13]\].

Ovarian cancer in a personal or family history was documented in three out of seven patients who carried a pathogenic *BRCA1/2* non-founder mutation. Additionally, in one case, unknown gynaecological cancer was reported in a paternal aunt. According to recent studies, the presence of ovarian cancer in personal or family history of pathogenic *BRCA1* founder-negative breast cancer patients increases the possibility of carrying previously undetected pathogenic *BRCA1/2* non-founder mutations \[[@CR30], [@CR31]\]. Recently, in a study published by *Couch* et al., ovarian cancer in family history was documented only in 1 of 54 pathogenic non-*BRCA1/2* mutation carriers with triple-negative breast cancer \[[@CR25]\].

In our study, no pathogenic mutations were detected in another 24 genes included in the panel. Some previously published studies demonstrated that the rate of pathogenic mutations in non-*BRCA1/2* genes ranged from 2.9 to 9.3% \[[@CR32]--[@CR35]\].

Four of the 16 (25%) patients were identified to have a variant of unknown significance (VUS) in *BRCA2*, *RAD50, CDH1* and *MRE11.* Unfortunately, due to an insufficient sample size in our study, we cannot elaborate upon those results.

Conclusion {#Sec8}
==========

*A relatively high incidence of pathogenic non-founder BRCA1/2 mutations* was *observed among patients with triple-negative familial breast cancer in a founder population.* The Manchester scoring system predicted the probability of non-founder pathogenic mutations with high accuracy.
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